IKT-901

N/A

Report date: 2026/03/19 16:53:34

Base Information

Drug NameIKT-901
Drug Alias Nameanti-CD3/anti-FAP bispecific T-cell engager (Icell Kealex)FAP-TEA-VVIKT-901
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Oncolytic virusBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsImmunostimulantsFibroblast activation protein alpha modulators +[4] 
TargetsProlyl endopeptidase FAPT cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIcell Kealex TherapeuticsBaylor College Of Medicine
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A